Vir Biotechnology (NASDAQ:VIR) Major Shareholder Sells $1,529,228.40 in Stock

Key Points

• Major shareholder Endurance (Cayman) Ltd Svf sold 249,060 shares of Vir Biotechnology at an average price of $6.14, totaling approximately $1.53 million, resulting in a 1.59% decrease in their ownership.
• Vir Biotechnology's stock has faced a 2.4% decline recently, trading at $5.72, with a 1-year range between $4.16 and $14.45.
• The company reported a loss of ($0.80) earnings per share for the last quarter, which was below analysts' expectations, and experienced a 60.5% decline in revenue year-over-year.

Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) major shareholder Endurance (Cayman) Ltd Svf sold 249,060 shares of the firm's stock in a transaction dated Thursday, October 9th. The stock was sold at an average price of $6.14, for a total value of $1,529,228.40. Following the completion of the transaction, the insider owned 15,372,309 shares in the company, valued at approximately $94,385,977.26. This trade represents a 1.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Large shareholders that own more than 10% of a company's stock are required to disclose their sales and purchases with the SEC.

Endurance (Cayman) Ltd Svf also recently made the following trade(s):

• On Friday, October 10th, Endurance (Cayman) Ltd Svf sold 2,300 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.08, for a total transaction of $13,984.00.
• On Wednesday, October 8th, Endurance (Cayman) Ltd Svf sold 466,242 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.05, for a total value of $2,820,764.10.
• On Tuesday, October 7th, Endurance (Cayman) Ltd Svf sold 72,133 shares of Vir Biotechnology stock. The shares were sold at an average price of $5.60, for a total value of $403,944.80.
• On Monday, October 6th, Endurance (Cayman) Ltd Svf sold 73,955 shares of Vir Biotechnology stock. The shares were sold at an average price of $5.69, for a total value of $420,803.95.
• On Friday, October 3rd, Endurance (Cayman) Ltd Svf sold 450,342 shares of Vir Biotechnology stock. The shares were sold at an average price of $5.56, for a total value of $2,503,901.52.

Vir Biotechnology Trading Down 2.4%

NASDAQ VIR traded down $0.14 during mid-day trading on Tuesday, reaching $5.72. 632,461 shares of the company's stock traded hands, compared to its average volume of 1,545,372. Vir Biotechnology, Inc. has a 1-year low of $4.16 and a 1-year high of $14.45. The company has a fifty day simple moving average of $5.07 and a 200-day simple moving average of $5.28. The company has a market cap of $794.62 million, a price-to-earnings ratio of -1.43 and a beta of 1.27.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.80) earnings per share for the quarter, missing analysts' consensus estimates of ($0.72) by ($0.08). The business had revenue of $1.21 million for the quarter, compared to analyst estimates of $2.38 million. Vir Biotechnology had a negative net margin of 2,895.94% and a negative return on equity of 50.22%. Vir Biotechnology's revenue for the quarter was down 60.5% compared to the same quarter last year. During the same quarter last year, the business earned ($1.02) EPS. Equities research analysts forecast that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current fiscal year.

Analysts Set New Price Targets

VIR has been the topic of several recent research reports. Raymond James Financial initiated coverage on Vir Biotechnology in a report on Friday, July 11th. They issued an "outperform" rating on the stock. Evercore ISI started coverage on Vir Biotechnology in a research note on Wednesday, September 3rd. They set an "outperform" rating and a $12.00 target price on the stock. HC Wainwright reaffirmed a "buy" rating and set a $15.00 target price on shares of Vir Biotechnology in a research note on Monday, September 15th. Bank of America upgraded Vir Biotechnology from a "neutral" rating to a "buy" rating and lifted their target price for the stock from $12.00 to $14.00 in a report on Wednesday, August 27th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Vir Biotechnology in a report on Tuesday. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, Vir Biotechnology has a consensus rating of "Moderate Buy" and a consensus price target of $17.30.

Institutional Trading of Vir Biotechnology

A number of institutional investors have recently bought and sold shares of the company. Clarius Group LLC boosted its position in Vir Biotechnology by 0.3% during the third quarter. Clarius Group LLC now owns 619,312 shares of the company's stock valued at $3,536,000 after purchasing an additional 1,777 shares during the last quarter. Squarepoint Ops LLC boosted its position in Vir Biotechnology by 99.9% during the second quarter. Squarepoint Ops LLC now owns 107,360 shares of the company's stock valued at $541,000 after purchasing an additional 53,662 shares during the last quarter. Hudson Bay Capital Management LP boosted its position in Vir Biotechnology by 17.7% during the second quarter. Hudson Bay Capital Management LP now owns 696,000 shares of the company's stock valued at $3,508,000 after purchasing an additional 104,580 shares during the last quarter. Public Sector Pension Investment Board boosted its position in Vir Biotechnology by 7.4% during the second quarter. Public Sector Pension Investment Board now owns 314,176 shares of the company's stock valued at $1,583,000 after purchasing an additional 21,598 shares during the last quarter. Finally, Corient Private Wealth LLC boosted its position in Vir Biotechnology by 100.7% during the second quarter. Corient Private Wealth LLC now owns 518,684 shares of the company's stock valued at $2,614,000 after purchasing an additional 260,308 shares during the last quarter. Institutional investors and hedge funds own 65.32% of the company's stock.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.